The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain

British Journal of Pharmacology

Volumn 134, Issue 1, 2001, Pages 46-57

  Sanchez, V ^a   Camarero, J ^a   Esteban, B ^a   Peter, M J ^a   Green, A R ^b,c   Colado, M I ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b DE MONTFORT UNIVERSITY   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

3,4 methylenedioxymethamphetamine; 5 hydroxytryptamine; Ecstasy; Fluoxetine; Fluvoxamine; Neuroprotection; Norfluoxetine

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; FLUOXETINE; FLUVOXAMINE; NORFLUOXETINE; PAROXETINE; SEROTONIN; SODIUM CHLORIDE; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ACCUMULATION; DRUG BINDING; DRUG EFFECT; HIPPOCAMPUS; HYPERTHERMIA; MALE; NERVE DEGENERATION; NERVE ENDING; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE LEVEL;

EID: 0034852341     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704230     Document Type: Article

References (73)

1. 2--dependent toxicity linked to release
2. Interactions of fluoxetine with metabolism of dopamine and serotonin in rat brain regions
3. Glutathione and N-acetylcysteine conjugates of α-methyldopamine produce serotonergic neurotoxicity: Possible role in methylenedioxyamphetamine-mediated neurotoxicity
4. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness
5. Effects of chronic antidepressant treatments on serotonin transporter function, density and mRNA level
6. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine
7. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction
8. Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins
9. Blockade of newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes
10. Effects of single and repeated oral administration of fluvoxamine on extracellular serotonin in the median raphe nucleus and dorsal hippocampus of the rat
11. Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity
12. 3H-tryptophan in rat brain
13. Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): Evidence from using CuZn-superoxide dismutase transgenic mice
14. 3H]5-HT uptake; effect of administration of various antidepressant treatments
15. The spin trap reagent α-phenyl-N-tert-butyl nitrone prevents 'ecstasy'-induced neurodegeneration of 5-hydroxytryptamine neurones
16. 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine
17. Studies on the role of dopamine in the degeneration oF 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration
18. A study of the neurotoxic effect of MDMA ('ecstasy') on 5-HT neurones in the brains of mothers and neonates Following administration of the drug during pregnancy
19. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine
20. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor mctabolizer phenotype
21. Carrier-dependent and Ca2+-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine
22. 3H]paroxetine binding in rat cortex
23. 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose
24. Interactions of methylene dioxymethamphetamine with monoamine transmitter release mechanisms in rat brain slices
25. Effect of 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine on the depletion of brain serotonin by 4-chloroamphetamine
26. Importance of duration of drug action in the antagonism of p-chloroamphetamine depletion of brain serotonin-comparison of fluoxetine and chlorimipramine
27. Changes in dopamine metabolism in rat forebrain regions after cessation of long-term fluoxetine treatment: Relationship with brain concentrations of fluoxetine and norfluoxetine
28. Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate
29. Integrative transporter-mediated release from cytoplasmic and vesicular 5-hydroxytryptamine stores in cultured neurons
30. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: Implications for serotonin-dopamine interactions
31. 3H]paroxetine binding to rat cortical membranes
32. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin
33. 5-Hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylenedioxymethamphetamine and related agents
34. Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ('ecstasy') to rats
35. Pharmacokinetics and antidepressant activity of fluoxetine in transgenic mice with elevated serum alpha-1-acid glycoprotein levels
36. Effects of serotonin uptake inhibitor, Lilly 110140, on transport of serotonin in rat and human blood platelets
37. 3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues
38. 3H]dopamine release from superfused rat brain slices
39. Detection of fluoxetine in brain, blood, liver and hair of rats using gas chromatography-mass spectrometry
40. Fluoxetine: Clinical pharmacology and physiologic disposition
41. MDMA (ecstasy) inhibition of MAO type A and type B: Comparisons with fenfluramine and fluoxetine (Prozac)
42. Protein measurement with the Folin phenol reagent
43. Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat
44. 3H-5-hydroxytryptamine
45. Evidence against MDMA-induced hyperthermia being mediated by 5-HT release in the brain
46. Neurotoxicity of MDMA and related compounds: Anatomic studies
47. 3H]serotonin from rat brain synaptosomes
48. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: Immunocytochemical evidence for neurotoxicity
49. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy')
50. 3H]-paroxetine
51. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism
52. Protein kinase C activation regulates human serotonin transporters in HEK-293 cells via altered cell surface expression
53. Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants
54. Phosphorylation and regulation of antidepressant-sensitive serotonin transporters
55. The molecular mechanism of 'ecstasy' [3,4-methylenedioxymethamphetamine (MDMA)]: Serotonin transporters are targets for MDMA-induced serotonin release
56. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding
57. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine
58. Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine
59. L-DOPA potentiation of the serotonergic deficits due to a single administration of 3,4-methylenedioxymethamphetamine to rats
60. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain
61. Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine
62. Alterations in hippocampal function following repeated exposure to the amphetamine derivative methylenedioxymethamphetamine ('ecstasy')
63. Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate
64. The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits
65. MDMA (3,4-methylenedioxymethamphetamine) inhibits the firing of dorsal raphe neurons in brain slices via release of serotonin
66. Prozac: Panacea or puzzle
67. 3H]monoamines into synaptosomes from different regions of rat brain
68. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine
69. Hydroxyl and peroxyl radical trapping by the monoamine oxidase-B inhibitors deprenyl and MDL 72,974A: Implications for protection of biological substrates
70. Overview of the pharmacokinetics of fluvoxamine
71. Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors
72. Norfluoxetine enantiomers as inhibitors of serotonin uptake in the rat brain
73. N-tert-butyl-alpha-phenylnitrone protects against 3,4-methylenedioxymethamphetamine-induced depletion of serotonin in rats